Spots Global Cancer Trial Database for immune reconstitution

Every month we try and update this database with for immune reconstitution cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation	NCT01882374	Hematologic Mal...	TXA127	18 Years -	Tarix Pharmaceuticals
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor	NCT00967343	Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat...	Donor lymphocyt...	18 Years - 65 Years	Kiadis Pharma
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor	NCT00967343	Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat...	Donor lymphocyt...	18 Years - 65 Years	Kiadis Pharma
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation	NCT01300611	Double Cord Blo... Acute Myelogeno... Myelodysplastic... Myelofibrosis Acute Lymphobla... Chronic Myelocy... Non Hodgkins Ly... Hodgkins Lympho... Chronic Lymphoc...	TXA127 300 mcg/... TXA127 1000 mcg...	18 Years - 60 Years	Tarix Pharmaceuticals
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor	NCT02500550	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	ATIR101 Haploidentical ... TBI regime Non-TBI regime	18 Years - 65 Years	Kiadis Pharma
Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant	NCT01540175	Solid Tumor Brain Tumor Lymphoma	Blood samples o...	- 21 Years	St. Jude Children's Research Hospital
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer	NCT02999854	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	ATIR101 Cyclophosphamid... T-cell depleted... T-cell replete ...	18 Years - 70 Years	Kiadis Pharma
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor	NCT02500550	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	ATIR101 Haploidentical ... TBI regime Non-TBI regime	18 Years - 65 Years	Kiadis Pharma
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation	NCT01300611	Double Cord Blo... Acute Myelogeno... Myelodysplastic... Myelofibrosis Acute Lymphobla... Chronic Myelocy... Non Hodgkins Ly... Hodgkins Lympho... Chronic Lymphoc...	TXA127 300 mcg/... TXA127 1000 mcg...	18 Years - 60 Years	Tarix Pharmaceuticals
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation	NCT01554254	Cord Blood Tran... Hematologic Mal... Inherited Metab...	TXA127	6 Months - 20 Years	Tarix Pharmaceuticals
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor	NCT01794299	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	ATIR	18 Years - 65 Years	Kiadis Pharma
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation	NCT01882374	Hematologic Mal...	TXA127	18 Years -	Tarix Pharmaceuticals
Chinese Herbal Medicine for Immune Reconstitution Following HSCT in Acute Leukemia Patients	NCT02580071	Acute Leukemia	Sheng-Yu-Tang	20 Years -	China Medical University Hospital

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: